Purpose of reviewBreast cancer is a heterogeneous disease, including different subtypes with their own biology, prognosis, clinical characteristics and treatment. To date, traditional clinical and pathological determinants remain the main factors guiding treatment decision-making; however, the development of multigene assays improved the ability to predict the risk of recurrence in patients with early-stage breast cancer. These tools underwent an extensive independent validation and have already been partly incorporated into clinical practice.Recent findingsThe current article summarizes current evidence for the use of the different genomic assays in clinical practice, their characteristics and validation studies. A few studies comparing available genomic assays revealed that they provide different information with a modest correlation and that they are not interchangeable; other trials are currently ongoing in this setting.SummaryVariability across different gene signatures may be a challenge for the optimal management of the individual patient, hence each assay should be used for the clinical setting in which it has been validated.

Harmonizing gene signatures to predict benefit from adjuvant chemotherapy in early breast cancer / C. Criscitiello, G. Viale, G. Curigliano. - In: CURRENT OPINION IN ONCOLOGY. - ISSN 1040-8746. - 31:6(2019 Nov), pp. 472-479. [10.1097/CCO.0000000000000570]

Harmonizing gene signatures to predict benefit from adjuvant chemotherapy in early breast cancer

C. Criscitiello
Primo
;
G. Viale
Penultimo
;
G. Curigliano
Ultimo
Conceptualization
2019

Abstract

Purpose of reviewBreast cancer is a heterogeneous disease, including different subtypes with their own biology, prognosis, clinical characteristics and treatment. To date, traditional clinical and pathological determinants remain the main factors guiding treatment decision-making; however, the development of multigene assays improved the ability to predict the risk of recurrence in patients with early-stage breast cancer. These tools underwent an extensive independent validation and have already been partly incorporated into clinical practice.Recent findingsThe current article summarizes current evidence for the use of the different genomic assays in clinical practice, their characteristics and validation studies. A few studies comparing available genomic assays revealed that they provide different information with a modest correlation and that they are not interchangeable; other trials are currently ongoing in this setting.SummaryVariability across different gene signatures may be a challenge for the optimal management of the individual patient, hence each assay should be used for the clinical setting in which it has been validated.
adjuvant chemotherapy; early breast cancer; genomic assays; precision medicine; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Female; Gene Expression Profiling; Humans; Predictive Value of Tests; Randomized Controlled Trials as Topic; Receptor, ErbB-2
Settore MED/06 - Oncologia Medica
Article (author)
File in questo prodotto:
File Dimensione Formato  
Harmonizing_gene_signatures_to_predict_benefit.3.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 220.85 kB
Formato Adobe PDF
220.85 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/824457
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact